We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Seegene Reveals New Real-Time PCR at AACC 2014

By LabMedica International staff writers
Posted on 29 Jul 2014
Seegene Inc. More...
(Eschborn, Germany), a developer of multiplex PCR technologies, revealed their “MuDT” technology at the AACC 2014 meeting. MuDT is a real-time polymerase chain reaction (PCR) technology that will cause a shift in the PCR instrument market. The technology doubles the multiplexing capacity of any existing real-time PCR instrument––thus maximizing the value of the installed base of these instruments.

MuDT technology can be applied to any existing real-time PCR instrument and transforms it into a more powerful system by doubling its multiplexing capacity without upgrading the hardware.

The biotechnology industry has relied on real-time PCR for at least 20 years a molecular diagnostics technology, because of its versatility, speed, and ease of use. Despite many attempts, the biotechnology industry has not made significant advances that satisfy the growing demand for increased multiplexing and target quantification using limited numbers of channels in a single tube. Even melt curve analysis, after amplification has many disadvantages, such as end-point analysis after amplification, extended turnaround time, lack of quantification, and melt temperature variation due to target sequence variations on probe binding regions.

Additional benefits of the technology include: easier detection of multiple targets in a single channel without requiring melt curve analysis after amplification, SNP genotyping (homozygous wild type or mutant, or heterozygous) in a single channel.

Seegene is a global developer of multiplex molecular technologies and multiplex clinical molecular diagnostics that can simultaneously detect multiple targets with sensitivity, specificity, and reproducibility. The company's products detect multipathogens with good reliability and throughput, ultimately providing an economical basis for saving time, labor, and cost.

Related Links:

Seegene 



Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
Thyroid Test
Anti-Thyroid EIA Test
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.